News

Second Generation MR Conditional Pacemakers Are the Only Offering Both Single- and Dual-Chamber Models in the U.S. BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced that the first U.S. patient has been...

Second Generation Single- and Dual-Chamber Pacemakers that Give Patients Access to MRI Scans Now Available in the U.S.   BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced that the Food and Drug Administration...

Working together to use AliveCor’s proven algorithms to optimize workflow for arrhythmia monitoring AliveCor, Inc. announced the launch of a cloud-based electrocardiogram (ECG) analytics program with Preventice Solutions, a strategic...

Boehringer Ingelheim Pharmaceuticals, Inc. today will present results from two analyses of the GLORIA™-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial...

First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the...

St. Jude Medical, Inc., a global medical device company, announced a new data analysis from the CHAMPION trial showing that heart failure (HF) patients with reduced ejection fraction on optimal doses of guideline directed medical therapy...

iRhythm Technologies, Inc. announced data presented during the American College of Cardiology (ACC) Scientific Sessions, which identified a high burden of paroxysmal, or episodic, arrhythmias among elderly men and women. Paroxysmal and...

The Get in Rhythm, Stay in Rhythm Atrial Fibrillation Patient Conference will bring together electrophysiologists, surgeons, and other specialists to help patients, their families, and caregivers learn more about atrial fibrillation, a...

AliveCor, Inc. announced the launch of the latest version of the AliveECG app, with two new FDA-cleared and CE-marked automated detectors that allow patients and physicians to focus on the ECGs that matter most. The new mobile app...

Boehringer Ingelheim Pharmaceuticals, Inc. announced it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA), requesting an Accelerated Approval pathway, for the use of idarucizumab to reverse the...